Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-07-09 | 2021-08-16 | 142275 |
| APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2021-09-17 | 2021-11-22 | 145837 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2022-01-07 | 2022-01-31 | 152310 |
| APO-GABAPENTIN | 600MG | TABLET | Resolved | 2019-01-09 | 2019-01-12 | 71662 |
| APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-10-08 | 2021-10-29 | 146904 |
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2017-03-11 | 2017-07-13 | 661 |
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2017-11-09 | 2017-12-19 | 28726 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2020-01-15 | 2020-02-10 | 103365 |
| APO-GABAPENTIN CAPSULES | 400MG | CAPSULE | Resolved | 2017-04-07 | 2017-09-15 | 5897 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2017-08-21 | 2017-10-04 | 20000 |
| APO-GABAPENTIN CAPSULES | 400MG | CAPSULE | Resolved | 2017-03-11 | 2017-03-29 | 604 |
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2017-06-06 | 2017-08-16 | 12064 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2018-02-26 | 2018-04-24 | 41145 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2017-11-28 | 2018-02-21 | 30998 |
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2018-04-02 | 2018-08-21 | 44497 |
| APO-GAIN LIQ 20MG/ML | 20MG | LIQUID | Resolved | 2017-04-12 | 2018-02-26 | 6554 |
| APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2023-09-28 | 2023-11-24 | 205486 |
| APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2024-03-27 | 2024-04-12 | 223555 |
| APO-GEFITINIB | 250MG | TABLET | Resolved | 2022-04-14 | 2022-06-24 | 158819 |
| APO-GEMFIBROZIL | 600MG | TABLET | Resolved | 2017-03-11 | 2019-11-26 | 610 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |